









Markets
/
Stocks
/
nasdaq-onc
/

Beigene Ltd

ONC

View Detailed Chart

300.650USD

-5.090-1.66%

Market hours （ET）Quotes delayed by 15 min

29.79BMarket Cap

LossP/E TTM



Beigene Ltd

300.650

-5.090-1.66%

Overview Company Financials

Financials

Intraday

30m

Today

-1.66%

5 Days

+1.71%

1 Month

+24.65%

6 Months

+32.61%

Year to Date

+62.77%

1 Year

+86.81%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 22 analysts

BUY

Current Rating

330.776

Target Price

12.31%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

BeOne Medicines AG

ONC

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(1)

Buy(9)

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

5.738

Buy

RSI(14)

72.350

Buy

STOCH(KDJ)(9,3,3)

83.866

Overbought

ATR(14)

9.090

High Vlolatility

CCI(14)

92.111

Neutral

Williams %R

5.228

Overbought

TRIX(12,20)

0.727

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

296.602

Buy

MA10

293.459

Buy

MA20

271.812

Buy

MA50

259.493

Buy

MA100

252.614

Buy

MA200

231.611

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

BeOne Medicines Ltd., formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Ticker SymbolONC

CompanyBeOne Medicines AG

CEOMr. John Victor Oyler

Website